logo

NorTrials

NorTrials is a national partnership to increase the number of clinical trials in Norway. NorTrials contributes to a more efficient infrastructure and increased collaboration on industry-funded clinical trials in Norway.

Norsk
Graphical user interface

NorTrials Feasibility Portal

NorTrials Feasibility Portal is a national entry point for companies that want to initiate clinical trials in Norway, with access to all Norwegian hospitals,.

NorTrials Feasibility Portal
Graphical user interface

What is NorTrials?

NorTrials is a partnership between the regional health authorities and the organisations for the pharmaceutical and medical device industries.
About us
A man and a woman talking

NorTrials Centres

NorTrials has established six dedicated clinical research centres within defined therapeutic areas. 

NorTrials Centres
Shape, circle

Patient Brochure on Clinical Trials

Association of the Pharmaceutical Industry in Norway (LMI), NorTrials and several patient associations have together produced a brochure on clinical trials, intended for patients and relatives.

Patient Brochure
Graphical user interface, diagram

News

  • A woman smiling for the camera
    7. november 2023
    Gathering Clinical Research Nurses and Coordinators to Solve Challenges Together

    Every month, Charlotte Helen Melby, coordinator of NorTrials Cancer, invites around 50 clinical research nurses and coordinators from 18 cancer departments around the country to share experiences and discuss challenges.

  • Meeting participants at the embassy residence
    23. oktober 2023
    Successful NorTrials Meeting in Madrid

    ESMO cancer congress is ongoging in Spain these days, and on Friday evening Norwegian clinicians and representatives from the international health industry met at the Norwegian embassy residence in Madrid.

  • A person wearing glasses
    20. oktober 2023
    New Communications Advisor at NorTrials

    Eline Feiring (48) will assist NorTrials Coordinating Unit with professional communication services in a 20% position.